+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Therapeutics Market by Drug Class, Distribution Channel, Route of Administration, Therapy Line - Global Forecast to 2030- Product Image
Gout Therapeutics Market by Drug Class, Distribution Channel, Route of Administration, Therapy Line - Global Forecast to 2030- Product Image
Sale

Gout Therapeutics Market by Drug Class, Distribution Channel, Route of Administration, Therapy Line - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904565
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gout therapeutics market is entering a new phase, defined by clinical innovation, evolving patient care models, and shifting economic priorities. Senior leaders face a landscape shaped by novel therapies, digital integration, and ongoing regulatory and supply chain complexities—demanding targeted strategies for growth and resilience.

Market Snapshot: Gout Therapeutics

The Gout Therapeutics Market grew from USD 3.05 billion in 2024 to USD 3.40 billion in 2025. It is expected to continue growing at a CAGR of 10.99%, reaching USD 5.71 billion by 2030. This upward trend is driven by major paradigm shifts in clinical practice, increased adoption of advanced therapies, and expanding demand worldwide. Companies are adapting to increased complexity in pricing and reimbursement while capturing value from both legacy and next-generation treatments in established and emerging markets.

Scope & Segmentation

This report delivers a precise outlook on the evolving market structure, technologies, and key segments:

  • Drug Classes: Anti-inflammatory agents (including colchicine, corticosteroids, ibuprofen, indomethacin, naproxen), uricase agents (pegloticase, rasburicase), uricosuric agents (benzbromarone, lesinurad, probenecid), and xanthine oxidase inhibitors (allopurinol, febuxostat, topiroxostat).
  • Distribution Channels: Hospital pharmacies (inpatient, outpatient), online pharmacies, and retail pharmacies.
  • Routes of Administration: Oral therapies, intravenous, and subcutaneous injectables.
  • Therapy Lines: First-line (nonsteroidal anti-inflammatory drugs, xanthine oxidase inhibitors), second-line (colchicine, uricosuric agents), and third-line (corticosteroids, uricase agents).
  • Regional Coverage: Americas (key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East and Africa (major European economies, selected Middle Eastern, African countries), and Asia-Pacific (China, India, Japan, Australia, leading Southeast Asian markets).
  • Leading Companies Analyzed: Takeda Pharmaceutical Company Limited, Horizon Therapeutics plc, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Viatris, Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals, Inc., Lupin Limited.

Key Takeaways for Decision-Makers

  • Innovative biologics and advanced xanthine oxidase inhibitors are reshaping treatment paradigms, particularly for refractory and complex gout cases.
  • Digital tools and real-world data infrastructure now enable remote monitoring and tailored patient management, optimizing dosing and improving therapy adherence.
  • Value-based models are increasingly central in contractual negotiations with payers, aligning reimbursement to measurable outcomes, such as fewer flares and reduced hospital admissions.
  • Diversification of supply chains and investments in continuous manufacturing bolster resilience against geopolitical and economic disruptions.
  • Regional variations in regulatory speed, clinical pathways, and health technology assessment require carefully tailored go-to-market and pricing strategies.

Tariff Impact on Gout Therapeutics

The introduction of United States tariffs in 2025 has led to increased costs for gout therapeutics, particularly through costlier imported ingredients and excipients. Stakeholders have responded by optimizing manufacturing locations and integrating supply chains to limit exposure. This has intensified contract negotiations and prompted some firms to advance automation and modernization across production sites. As a result, procurement teams and group purchasing organizations now navigate more complex formulary placement challenges, while payers emphasize stringent utilization management to maintain budget stability. Risk-sharing agreements are emerging as a way to sustain access amid rising list prices.

Methodology & Data Sources

This analysis is grounded in a rigorous research approach that combines primary interviews with opinion leaders—rheumatologists, pharmacists, payers—and extensive secondary review of regulatory filings, clinical trials, patents, and industry reports. Advanced data triangulation and statistical modeling support segmentation accuracy and region-specific insights. All outputs have been peer-reviewed to ensure analytical reliability and clarity.

Why This Report Matters

  • Gain a strategic overview of current market shifts, enabling proactive responses to regulatory, technological, and channel challenges.
  • Leverage segmentation insights and competitive benchmarking to inform portfolio prioritization and resource allocation.
  • Support forward-looking decisions with data-driven forecasts and actionable recommendations tailored to core stakeholder needs.

Conclusion

The gout therapeutics market is rapidly evolving, with digital health, regulatory policies, and segment expansion driving competitive dynamics. Senior leaders can use this research to optimize strategies and capture emerging growth opportunities, while managing risk and ensuring patient-centric value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gout Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Anti-Inflammatory Agent
8.2.1. Colchicine
8.2.2. Corticosteroid
8.2.3. Nonsteroidal Anti-Inflammatory Drug
8.2.3.1. Ibuprofen
8.2.3.2. Indomethacin
8.2.3.3. Naproxen
8.3. Uricase Agent
8.3.1. Pegloticase
8.3.2. Rasburicase
8.4. Uricosuric Agent
8.4.1. Benzbromarone
8.4.2. Lesinurad
8.4.3. Probenecid
8.5. Xanthine Oxidase Inhibitor
8.5.1. Allopurinol
8.5.2. Febuxostat
8.5.3. Topiroxostat
9. Gout Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Inpatient Pharmacy
9.2.2. Outpatient Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Gout Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
11. Gout Therapeutics Market, by Therapy Line
11.1. Introduction
11.2. First Line
11.2.1. Nonsteroidal Anti-Inflammatory Drug
11.2.1.1. Ibuprofen
11.2.1.2. Indomethacin
11.2.1.3. Naproxen
11.2.2. Xanthine Oxidase Inhibitor
11.2.2.1. Allopurinol
11.2.2.2. Febuxostat
11.3. Second Line
11.3.1. Colchicine
11.3.2. Uricosuric Agent
11.3.2.1. Benzbromarone
11.3.2.2. Lesinurad
11.3.2.3. Probenecid
11.4. Third Line
11.4.1. Corticosteroid
11.4.1.1. Methylprednisolone
11.4.1.2. Prednisone
11.4.2. Uricase Agent
11.4.2.1. Pegloticase
11.4.2.2. Rasburicase
12. Americas Gout Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Gout Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Gout Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Takeda Pharmaceutical Company Limited
15.3.2. Horizon Therapeutics plc
15.3.3. AstraZeneca plc
15.3.4. Teva Pharmaceutical Industries Ltd.
15.3.5. Viatris, Inc.
15.3.6. Sandoz International GmbH
15.3.7. Sun Pharmaceutical Industries Ltd.
15.3.8. Dr. Reddy’s Laboratories Ltd.
15.3.9. Amneal Pharmaceuticals, Inc.
15.3.10. Lupin Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. GOUT THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. GOUT THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. GOUT THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GOUT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TOPIROXOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY INDOMETHACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY BENZBROMARONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY LESINURAD, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PROBENECID, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY RASBURICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 113. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 115. CANADA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 116. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 117. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 118. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 119. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. CANADA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 121. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. CANADA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 123. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 124. CANADA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 125. CANADA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 126. CANADA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 127. CANADA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 128. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 129. CANADA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 130. CANADA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 131. CANADA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 132. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 134. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 135. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 136. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 137. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 138. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 142. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 144. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 145. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 146. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 148. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 149. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 150. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 228. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 230. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 231. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 232. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 233. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 234. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 236. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 239. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 240. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 241. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 242. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 243. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 244. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 245. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 246. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 247. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 249. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 250. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 251. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 252. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 253. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 255. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 257. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 258. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 259. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 260. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 261. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 262. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 263. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 264. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 265. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 274. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 276. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 277. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 278. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 279. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 280. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 281. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 282. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 283. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 284. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 285. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 287. ITALY GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 288. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 289. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 290. ITALY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 291. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. ITALY GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 293. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ITALY GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 295. ITALY GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 296. ITALY GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 297. ITALY GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 298. ITALY GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 299. ITALY GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 300. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 301. ITALY GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 302. ITALY GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 303. ITALY GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 304. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 306. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 307. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 308. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 309. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 310. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 312. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 314. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 315. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2030 (USD MILLION)
TABLE 316. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 317. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 318. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2030 (USD MILLION)
TABLE 319. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 320. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY THIRD LINE, 2018-2030 (USD MILLION)
TABLE 321. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 322. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY AGENT, 2018-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUG, 2018-2030 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY URICASE AGENT, 2018-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIC AGENT, 2018-2030 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 331. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gout Therapeutics market report include:
  • Takeda Pharmaceutical Company Limited
  • Horizon Therapeutics plc
  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Lupin Limited

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.71 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gout Therapeutics Market Report 2025 - Product Image

Gout Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Gout Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), Disease Condition, Distribution Channel (Hospital Pharmacy), and Region with Growth Forecasts, 2025-2030 - Product Image

Gout Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), Disease Condition, Distribution Channel (Hospital Pharmacy), and Region with Growth Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Gout Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Gout Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From
Chronic Gout - Pipeline Insight, 2025 - Product Image

Chronic Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Gout Drug Market

The Gout Drug market is a subset of the Immune Disorders Drugs market, which includes treatments for a variety of conditions related to the immune system. Gout drugs are used to reduce the inflammation and pain associated with gout, a type of arthritis caused by the buildup of uric acid in the joints. These drugs can be taken orally or injected directly into the affected joint. Commonly prescribed gout drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Gout drugs are typically prescribed by a doctor and are available in both generic and brand-name forms. The cost of these drugs can vary depending on the type of drug, the dosage, and the form in which it is taken. Some companies in the Gout Drug market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.